Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $45.3 million.

  • IDEAYA Biosciences' Accumulated Expenses rose 6110.64% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year increase of 6110.64%. This contributed to the annual value of $30.4 million for FY2024, which is 6182.55% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Accumulated Expenses stood at $45.3 million for Q3 2025, which was up 6110.64% from $37.8 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Accumulated Expenses ranged from a high of $45.3 million in Q3 2025 and a low of $7.8 million during Q1 2021
  • For the 5-year period, IDEAYA Biosciences' Accumulated Expenses averaged around $20.4 million, with its median value being $17.0 million (2022).
  • In the last 5 years, IDEAYA Biosciences' Accumulated Expenses surged by 8973.77% in 2021 and then crashed by 948.86% in 2023.
  • IDEAYA Biosciences' Accumulated Expenses (Quarter) stood at $12.3 million in 2021, then skyrocketed by 37.98% to $17.0 million in 2022, then rose by 10.34% to $18.8 million in 2023, then soared by 61.83% to $30.4 million in 2024, then skyrocketed by 49.11% to $45.3 million in 2025.
  • Its Accumulated Expenses stands at $45.3 million for Q3 2025, versus $37.8 million for Q2 2025 and $32.9 million for Q1 2025.